Hypoglycaemia risk increases when GLP-1 agonists are combined with insulin or sulphonylureas, requiring careful medication review and dose adjustment
Kevin Sheng-Kai Ma, DDS, FRSPH, FRSM, international scholar at the Center for Global Health at the Perelman School of Medicine at the University of Pennsylvania and lead author of this study, told Medical News Today that he and his colleagues were not surprised by these findings, as these [obesity and obesity-related issues] are indications for GLP-1RA that have been approved in recent years. That said, clinicians are encouraged to monitor and continue assessing patients receiving GLP-1RA [drugs], he advised
Elite nutritional supplement companies offered a combination of adenosylcobalamin and methylcobalamin, claiming better body compatibility and superior effectiveness
A 30-day supply of the injectables Zepbound (tirzepatide) and Wegovy (semaglutide) has a list price of roughly $1,000 per month
What are the claims
No personal details